<\/h1><\/span><\/div><\/div><\/div>Structure-Based Immunogen Design<\/h3><\/h2><\/div><\/h1><\/span><\/div><\/div><\/div>![](\"https:\/\/lab.research.sickkids.ca\/julien\/wp-content\/uploads\/sites\/24\/2016\/02\/Antigens.png\")
<\/a><\/span><\/div><\/div>Malaria and HIV-1 are two of the most devastating and ongoing health burdens, particularly in the developing world. Protective vaccines against these pathogens remain elusive, in part because of our inability to induce by vaccination high-neutralizing antibody titers against conserved antigenic sites.<\/span><\/p>\nWe use epitope-selective, structure-based protein design strategies to generate novel immunogens that elicit antibodies blocking the function of critical malaria and HIV-1 proteins.<\/span><\/p>\n<\/div><\/div><\/div><\/div><\/h1><\/span><\/div><\/div><\/div>Cell-Targeting Nanocages<\/h3><\/h2><\/div><\/h1><\/span><\/div><\/div><\/div>![](\"https:\/\/lab.research.sickkids.ca\/julien\/wp-content\/uploads\/sites\/24\/2016\/02\/nanocages-copy.png\")
<\/a><\/span><\/div><\/div>We study the fundamentals of protein nanoparticle assembly and use protein engineering and biophysical techniques to broaden the development of stable glycoprotein nanocages. <\/span><\/p>\nOur objective is to uncover the fundamentals of protein nanoparticle self-assembly to engineer the delivery of specific signals to target cells.<\/span><\/p>\n<\/div><\/div><\/div><\/div><\/h1><\/span><\/div><\/div><\/div>Structural Delineation of B cell Receptors<\/h3><\/h2><\/div>
Structure-Based Immunogen Design<\/h3><\/h2><\/div><\/h1><\/span><\/div><\/div><\/div><\/a><\/span><\/div><\/div>Malaria and HIV-1 are two of the most devastating and ongoing health burdens, particularly in the developing world. Protective vaccines against these pathogens remain elusive, in part because of our inability to induce by vaccination high-neutralizing antibody titers against conserved antigenic sites.<\/span><\/p>\nWe use epitope-selective, structure-based protein design strategies to generate novel immunogens that elicit antibodies blocking the function of critical malaria and HIV-1 proteins.<\/span><\/p>\n<\/div><\/div><\/div><\/div><\/h1><\/span><\/div><\/div><\/div>Cell-Targeting Nanocages<\/h3><\/h2><\/div><\/h1><\/span><\/div><\/div><\/div><\/a><\/span><\/div><\/div>We study the fundamentals of protein nanoparticle assembly and use protein engineering and biophysical techniques to broaden the development of stable glycoprotein nanocages. <\/span><\/p>\nOur objective is to uncover the fundamentals of protein nanoparticle self-assembly to engineer the delivery of specific signals to target cells.<\/span><\/p>\n<\/div><\/div><\/div><\/div><\/h1><\/span><\/div><\/div><\/div>Structural Delineation of B cell Receptors<\/h3><\/h2><\/div>
<\/h1><\/span><\/div><\/div><\/div><\/a><\/span><\/div><\/div>Malaria and HIV-1 are two of the most devastating and ongoing health burdens, particularly in the developing world. Protective vaccines against these pathogens remain elusive, in part because of our inability to induce by vaccination high-neutralizing antibody titers against conserved antigenic sites.<\/span><\/p>\nWe use epitope-selective, structure-based protein design strategies to generate novel immunogens that elicit antibodies blocking the function of critical malaria and HIV-1 proteins.<\/span><\/p>\n<\/div><\/div><\/div><\/div><\/h1><\/span><\/div><\/div><\/div>Cell-Targeting Nanocages<\/h3><\/h2><\/div><\/h1><\/span><\/div><\/div><\/div><\/a><\/span><\/div><\/div>We study the fundamentals of protein nanoparticle assembly and use protein engineering and biophysical techniques to broaden the development of stable glycoprotein nanocages. <\/span><\/p>\nOur objective is to uncover the fundamentals of protein nanoparticle self-assembly to engineer the delivery of specific signals to target cells.<\/span><\/p>\n<\/div><\/div><\/div><\/div><\/h1><\/span><\/div><\/div><\/div>Structural Delineation of B cell Receptors<\/h3><\/h2><\/div>
<\/a><\/span><\/div><\/div>Malaria and HIV-1 are two of the most devastating and ongoing health burdens, particularly in the developing world. Protective vaccines against these pathogens remain elusive, in part because of our inability to induce by vaccination high-neutralizing antibody titers against conserved antigenic sites.<\/span><\/p>\n We use epitope-selective, structure-based protein design strategies to generate novel immunogens that elicit antibodies blocking the function of critical malaria and HIV-1 proteins.<\/span><\/p>\n<\/div> We study the fundamentals of protein nanoparticle assembly and use protein engineering and biophysical techniques to broaden the development of stable glycoprotein nanocages. <\/span><\/p>\n Our objective is to uncover the fundamentals of protein nanoparticle self-assembly to engineer the delivery of specific signals to target cells.<\/span><\/p>\n<\/div><\/h1><\/span>
Cell-Targeting Nanocages<\/h3><\/h2><\/div>
<\/h1><\/span>
<\/a><\/span><\/div><\/div><\/h1><\/span>
Structural Delineation of B cell Receptors<\/h3><\/h2><\/div>